Lukens AK, Heidebrecht RW, Mulrooney C, et al. Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors. J Infect Dis. 2015;211(7):1097-103. doi:10.1093/infdis/jiu565.

Patel V, Mazitschek R, Coleman B, et al. Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. J Med Chem. 2009;52(8):2185-7. doi:10.1021/jm801654y.

Dandapani S, Comer E, Duvall JR, Munoz B. Hits, leads and drugs against malaria through diversity-oriented synthesis. Future Med Chem. 2012;4(18):2279-94. doi:10.4155/fmc.12.178.

Gunawardena S, Daniels RF, Yahathugoda TC, et al. Case report of Plasmodium ovale curtisi malaria in Sri Lanka: relevance for the maintenance of elimination status. BMC Infect Dis. 2017;17(1):307. doi:10.1186/s12879-017-2411-z.

Cerqueira GC, Cheeseman IH, Schaffner SF, et al. Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. Genome Biol. 2017;18(1):78. doi:10.1186/s13059-017-1204-4.

Mukherjee A, Bopp S, Magistrado P, et al. Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia. Malar J. 2017;16(1):195. doi:10.1186/s12936-017-1845-5.

Hupalo DN, Luo Z, Melnikov A, et al. Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax. Nat Genet. 2016;48(8):953-8. doi:10.1038/ng.3588.

Maetani M, Zoller J, Melillo B, et al. Synthesis of a Bicyclic Azetidine with In Vivo Antimalarial Activity Enabled by Stereospecific, Directed C(sp)-H Arylation. J Am Chem Soc. 2017;139(32):11300-11306. doi:10.1021/jacs.7b06994.

Silva AF, Torres MDT, Silva LS, et al. Angiotensin II-derived constrained peptides with antiplasmodial activity and suppressed vasoconstriction. Sci Rep. 2017;7(1):14326. doi:10.1038/s41598-017-14642-z.

Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199. doi:10.1126/science.aan4472.